Treatment of recurrent severe hemoptysis in cystic fibrosis with tranexamic acid

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Major hemoptysis is a potentially life-threatening complication of cystic fibrosis (CF) lung disease. Bronchial artery embolization (BAE) along with treatment of a CF pulmonary exacerbation has become the most widely used therapeutic approach for major hemoptysis in CF. However, BAE has been associated with severe complications, especially when bronchial artery to spinal artery anastomoses are present. This case study describes the successful treatment of major hemoptysis in CF with tranexamic acid, in an individual in whom 12 previous BAE procedures had been performed and further procedures were contraindicated secondary to bronchial artery to spinal artery collaterals. Recurrence of the hemoptysis occurred after attempts had been made to withdraw the tranexamic acid. Tranexamic acid was resumed with resolution of the hemoptysis, and the therapy has been used continuously for 13 months without any complications.

Original languageEnglish (US)
Pages (from-to)91-94
Number of pages4
JournalRespiration
Volume68
Issue number1
DOIs
StatePublished - Mar 6 2001

Fingerprint

Bronchial Arteries
Tranexamic Acid
Hemoptysis
Cystic Fibrosis
Arteries
Lung Diseases
Recurrence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Physiology

Cite this

@article{166b01cd1f1e4b3db55341e3a27a4504,
title = "Treatment of recurrent severe hemoptysis in cystic fibrosis with tranexamic acid",
abstract = "Major hemoptysis is a potentially life-threatening complication of cystic fibrosis (CF) lung disease. Bronchial artery embolization (BAE) along with treatment of a CF pulmonary exacerbation has become the most widely used therapeutic approach for major hemoptysis in CF. However, BAE has been associated with severe complications, especially when bronchial artery to spinal artery anastomoses are present. This case study describes the successful treatment of major hemoptysis in CF with tranexamic acid, in an individual in whom 12 previous BAE procedures had been performed and further procedures were contraindicated secondary to bronchial artery to spinal artery collaterals. Recurrence of the hemoptysis occurred after attempts had been made to withdraw the tranexamic acid. Tranexamic acid was resumed with resolution of the hemoptysis, and the therapy has been used continuously for 13 months without any complications.",
author = "Gavin Graff",
year = "2001",
month = "3",
day = "6",
doi = "10.1159/000050470",
language = "English (US)",
volume = "68",
pages = "91--94",
journal = "Respiration; international review of thoracic diseases",
issn = "0025-7931",
publisher = "S. Karger AG",
number = "1",

}

Treatment of recurrent severe hemoptysis in cystic fibrosis with tranexamic acid. / Graff, Gavin.

In: Respiration, Vol. 68, No. 1, 06.03.2001, p. 91-94.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of recurrent severe hemoptysis in cystic fibrosis with tranexamic acid

AU - Graff, Gavin

PY - 2001/3/6

Y1 - 2001/3/6

N2 - Major hemoptysis is a potentially life-threatening complication of cystic fibrosis (CF) lung disease. Bronchial artery embolization (BAE) along with treatment of a CF pulmonary exacerbation has become the most widely used therapeutic approach for major hemoptysis in CF. However, BAE has been associated with severe complications, especially when bronchial artery to spinal artery anastomoses are present. This case study describes the successful treatment of major hemoptysis in CF with tranexamic acid, in an individual in whom 12 previous BAE procedures had been performed and further procedures were contraindicated secondary to bronchial artery to spinal artery collaterals. Recurrence of the hemoptysis occurred after attempts had been made to withdraw the tranexamic acid. Tranexamic acid was resumed with resolution of the hemoptysis, and the therapy has been used continuously for 13 months without any complications.

AB - Major hemoptysis is a potentially life-threatening complication of cystic fibrosis (CF) lung disease. Bronchial artery embolization (BAE) along with treatment of a CF pulmonary exacerbation has become the most widely used therapeutic approach for major hemoptysis in CF. However, BAE has been associated with severe complications, especially when bronchial artery to spinal artery anastomoses are present. This case study describes the successful treatment of major hemoptysis in CF with tranexamic acid, in an individual in whom 12 previous BAE procedures had been performed and further procedures were contraindicated secondary to bronchial artery to spinal artery collaterals. Recurrence of the hemoptysis occurred after attempts had been made to withdraw the tranexamic acid. Tranexamic acid was resumed with resolution of the hemoptysis, and the therapy has been used continuously for 13 months without any complications.

UR - http://www.scopus.com/inward/record.url?scp=0035101063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035101063&partnerID=8YFLogxK

U2 - 10.1159/000050470

DO - 10.1159/000050470

M3 - Article

VL - 68

SP - 91

EP - 94

JO - Respiration; international review of thoracic diseases

JF - Respiration; international review of thoracic diseases

SN - 0025-7931

IS - 1

ER -